CL vs KMB: How Colgate-Palmolive and Kimberly-Clark Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: KMB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CL and KMB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CL and KMB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Kimberly-Clark is a consumer staples company that makes and sells personal care and tissue products under household brand names. Its portfolio includes Huggies diapers, Pull-Ups training pants, Kotex feminine care, Depend and Poise adult incontinence products, Kleenex tissues, Cottonelle and Scott bath tissue, and Viva paper towels. The company organizes around three segments: Personal Care (its largest and most profitable), Consumer Tissue, and a professional/away-from-home business serving offices, restaurants, and institutions (sold under the Kimberly-Clark Professional banner). Roughly half of revenue comes from outside North America, with meaningful exposure to developing and emerging markets where category penetration is still rising. Kimberly-Clark makes money by selling repeat-purchase, non-discretionary household essentials at scale, leaning on brand strength, retail distribution, and manufacturing efficiency. The business is a classic defensive staple: steady demand, modest organic growth, and a long dividend history. Headquartered in Irving, Texas, it has been a Dividend Aristocrat for decades.

Full KMB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.
• KMB drivers: Defensive, repeat-purchase demand; Emerging-market category growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. For KMB, kimberly-Clark sells largely commoditized products where private-label store brands compete aggressively on price, capping pricing power and pressuring volumes when consumers trade down.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CL if you believe its drivers more; KMB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CL and KMB guides.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

KMB. Kimberly-Clark trades at a defensive-staples multiple, lower than faster-growing consumer names but supported by a high, durable dividend yield. The valuation reflects slow organic growth offset by predictable cash flow and decades of dividend increases. It tends to be valued like a bond proxy, with the multiple sensitive to interest rates and the dividend yield as the primary anchor for income investors.

Headline figures (approximate, early 2026): CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King); KMB shows revenue (ttm) ~$20 billion, operating margin ~16%, net income (ttm) ~$2.5 billion, p/e (ttm) ~18x.

CL and KMB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CL and KMB exposure against your real portfolio. It is not an investment adviser.